The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback